
Computational Drug Discovery/Computer-Aided Drug Discovery is an effective strategy for accelerating and economizing drug discovery and development process. Because of the dramatic increase in the availability of biological macromolecule and small molecule information, the applicability of computational drug discovery has been extended and broadly applied to nearly every stage in the drug discovery and development workflow, including target identification and validation, lead discovery and optimization and preclinical tests. Over the past decades, computational drug discovery methods such as molecular docking, pharmacophore modeling and mapping, de novo design, molecular similarity calculation and sequence-based virtual screening have been greatly improved.
Highlights
The global Computational Drug Discovery market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Computational Drug Discovery is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Computational Drug Discovery is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Computational Drug Discovery in Oncological Disorders is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Computational Drug Discovery include AMRI, Charles River, ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù, Evotec, Bayers, GVK Biosciences, AstraZeneca, BioDuro and BOC Sciences, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Computational Drug Discovery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Computational Drug Discovery.
The Computational Drug Discovery market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Computational Drug Discovery market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Computational Drug Discovery companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AMRI
Charles River
³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù
Evotec
Bayers
GVK Biosciences
AstraZeneca
BioDuro
BOC Sciences
Aris Pharmaceuticals
ChemDiv
RTI International
XRQTC
Pharmaron
Segment by Type
Structure-based Drug Design (SBDD)
Ligand-based Drug Design (LBDD)
Sequence-based Approaches
Segment by Application
Oncological Disorders
Neurological Disorders
Immunological Disorders
Infectious Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Computational Drug Discovery companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Computational Drug Discovery Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Structure-based Drug Design (SBDD)
1.2.3 Ligand-based Drug Design (LBDD)
1.2.4 Sequence-based Approaches
1.3 Market by Application
1.3.1 Global Computational Drug Discovery Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oncological Disorders
1.3.3 Neurological Disorders
1.3.4 Immunological Disorders
1.3.5 Infectious Diseases
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Computational Drug Discovery Market Perspective (2018-2029)
2.2 Computational Drug Discovery Growth Trends by Region
2.2.1 Global Computational Drug Discovery Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Computational Drug Discovery Historic Market Size by Region (2018-2023)
2.2.3 Computational Drug Discovery Forecasted Market Size by Region (2024-2029)
2.3 Computational Drug Discovery Market Dynamics
2.3.1 Computational Drug Discovery Industry Trends
2.3.2 Computational Drug Discovery Market Drivers
2.3.3 Computational Drug Discovery Market Challenges
2.3.4 Computational Drug Discovery Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Computational Drug Discovery Players by Revenue
3.1.1 Global Top Computational Drug Discovery Players by Revenue (2018-2023)
3.1.2 Global Computational Drug Discovery Revenue Market Share by Players (2018-2023)
3.2 Global Computational Drug Discovery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Computational Drug Discovery Revenue
3.4 Global Computational Drug Discovery Market Concentration Ratio
3.4.1 Global Computational Drug Discovery Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Computational Drug Discovery Revenue in 2022
3.5 Computational Drug Discovery Key Players Head office and Area Served
3.6 Key Players Computational Drug Discovery Product Solution and Service
3.7 Date of Enter into Computational Drug Discovery Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Computational Drug Discovery Breakdown Data by Type
4.1 Global Computational Drug Discovery Historic Market Size by Type (2018-2023)
4.2 Global Computational Drug Discovery Forecasted Market Size by Type (2024-2029)
5 Computational Drug Discovery Breakdown Data by Application
5.1 Global Computational Drug Discovery Historic Market Size by Application (2018-2023)
5.2 Global Computational Drug Discovery Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Computational Drug Discovery Market Size (2018-2029)
6.2 North America Computational Drug Discovery Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Computational Drug Discovery Market Size by Country (2018-2023)
6.4 North America Computational Drug Discovery Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Computational Drug Discovery Market Size (2018-2029)
7.2 Europe Computational Drug Discovery Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Computational Drug Discovery Market Size by Country (2018-2023)
7.4 Europe Computational Drug Discovery Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Computational Drug Discovery Market Size (2018-2029)
8.2 Asia-Pacific Computational Drug Discovery Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Computational Drug Discovery Market Size by Region (2018-2023)
8.4 Asia-Pacific Computational Drug Discovery Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Computational Drug Discovery Market Size (2018-2029)
9.2 Latin America Computational Drug Discovery Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Computational Drug Discovery Market Size by Country (2018-2023)
9.4 Latin America Computational Drug Discovery Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Computational Drug Discovery Market Size (2018-2029)
10.2 Middle East & Africa Computational Drug Discovery Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Computational Drug Discovery Market Size by Country (2018-2023)
10.4 Middle East & Africa Computational Drug Discovery Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AMRI
11.1.1 AMRI Company Detail
11.1.2 AMRI Business Overview
11.1.3 AMRI Computational Drug Discovery Introduction
11.1.4 AMRI Revenue in Computational Drug Discovery Business (2018-2023)
11.1.5 AMRI Recent Development
11.2 Charles River
11.2.1 Charles River Company Detail
11.2.2 Charles River Business Overview
11.2.3 Charles River Computational Drug Discovery Introduction
11.2.4 Charles River Revenue in Computational Drug Discovery Business (2018-2023)
11.2.5 Charles River Recent Development
11.3 ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù
11.3.1 ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù Company Detail
11.3.2 ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù Business Overview
11.3.3 ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù Computational Drug Discovery Introduction
11.3.4 ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù Revenue in Computational Drug Discovery Business (2018-2023)
11.3.5 ³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù Recent Development
11.4 Evotec
11.4.1 Evotec Company Detail
11.4.2 Evotec Business Overview
11.4.3 Evotec Computational Drug Discovery Introduction
11.4.4 Evotec Revenue in Computational Drug Discovery Business (2018-2023)
11.4.5 Evotec Recent Development
11.5 Bayers
11.5.1 Bayers Company Detail
11.5.2 Bayers Business Overview
11.5.3 Bayers Computational Drug Discovery Introduction
11.5.4 Bayers Revenue in Computational Drug Discovery Business (2018-2023)
11.5.5 Bayers Recent Development
11.6 GVK Biosciences
11.6.1 GVK Biosciences Company Detail
11.6.2 GVK Biosciences Business Overview
11.6.3 GVK Biosciences Computational Drug Discovery Introduction
11.6.4 GVK Biosciences Revenue in Computational Drug Discovery Business (2018-2023)
11.6.5 GVK Biosciences Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Computational Drug Discovery Introduction
11.7.4 AstraZeneca Revenue in Computational Drug Discovery Business (2018-2023)
11.7.5 AstraZeneca Recent Development
11.8 BioDuro
11.8.1 BioDuro Company Detail
11.8.2 BioDuro Business Overview
11.8.3 BioDuro Computational Drug Discovery Introduction
11.8.4 BioDuro Revenue in Computational Drug Discovery Business (2018-2023)
11.8.5 BioDuro Recent Development
11.9 BOC Sciences
11.9.1 BOC Sciences Company Detail
11.9.2 BOC Sciences Business Overview
11.9.3 BOC Sciences Computational Drug Discovery Introduction
11.9.4 BOC Sciences Revenue in Computational Drug Discovery Business (2018-2023)
11.9.5 BOC Sciences Recent Development
11.10 Aris Pharmaceuticals
11.10.1 Aris Pharmaceuticals Company Detail
11.10.2 Aris Pharmaceuticals Business Overview
11.10.3 Aris Pharmaceuticals Computational Drug Discovery Introduction
11.10.4 Aris Pharmaceuticals Revenue in Computational Drug Discovery Business (2018-2023)
11.10.5 Aris Pharmaceuticals Recent Development
11.11 ChemDiv
11.11.1 ChemDiv Company Detail
11.11.2 ChemDiv Business Overview
11.11.3 ChemDiv Computational Drug Discovery Introduction
11.11.4 ChemDiv Revenue in Computational Drug Discovery Business (2018-2023)
11.11.5 ChemDiv Recent Development
11.12 RTI International
11.12.1 RTI International Company Detail
11.12.2 RTI International Business Overview
11.12.3 RTI International Computational Drug Discovery Introduction
11.12.4 RTI International Revenue in Computational Drug Discovery Business (2018-2023)
11.12.5 RTI International Recent Development
11.13 XRQTC
11.13.1 XRQTC Company Detail
11.13.2 XRQTC Business Overview
11.13.3 XRQTC Computational Drug Discovery Introduction
11.13.4 XRQTC Revenue in Computational Drug Discovery Business (2018-2023)
11.13.5 XRQTC Recent Development
11.14 Pharmaron
11.14.1 Pharmaron Company Detail
11.14.2 Pharmaron Business Overview
11.14.3 Pharmaron Computational Drug Discovery Introduction
11.14.4 Pharmaron Revenue in Computational Drug Discovery Business (2018-2023)
11.14.5 Pharmaron Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AMRI
Charles River
³§³¦³ó°ùö»å¾±²Ô²µ±ð°ù
Evotec
Bayers
GVK Biosciences
AstraZeneca
BioDuro
BOC Sciences
Aris Pharmaceuticals
ChemDiv
RTI International
XRQTC
Pharmaron
Ìý
Ìý
*If Applicable.
